ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that its 'raison d'etre' has been unanimously approved by all shareholders represented at the last General Meeting on June 11, 2021, and will now be included in the company's articles of association.

This 'raison d'etre' will enlighten the company's future strategic choices and long-term guidance at the heart of the public health, economic and societal challenges of today and tomorrow. A clear and strong commitment to an ESG approach for a strategic model that creates even more positive impacts in healthcare Committed to an ESG approach, ABIONYX Pharma affirms its willingness to move towards a strategic model that creates even more positive impact for all its stakeholders.

The 'raison d'etre', co-constructed with its collaborators and stakeholders, which is 'to develop innovative therapies in indications with no effective or existing treatment, even the rarest ones, for the benefit of patients' is the coherent and conscious outcome of all the developments carried out by ABIONYX Pharma over the last two years. Following an in-depth review of the high-potential products in development in the company's portfolio, the advanced and solid innovation skills of its employees, and the increasingly positive impact on all of its stakeholders (patients, physicians, hospitals and caregivers, suppliers, shareholders, etc.), the company has been able to assess the positive effects of the innovative development of one of its products, CER-001 : first in an ultra-rare renal disease within the framework of a compassionate use thanks to nominative Temporary Use Authorizations, 2/2 - then in a Phase II clinical trial in a disease affecting more than 2 million people worldwide in sepsis at high risk of Acute Kidney Injury, - finally, in the context of extending the potential of the innovation to ophthalmological indications, the result of an unprecedented decompartmentalization between medical specialties such as nephrology and ophthalmology thanks to the pleiotropic action of natural HDL. This 'raison d'etre' marks the continuation of a very engaging process for the company, but also the formalization of the strategy initiated since 2019 by ABIONYX Pharma to accelerate its evolution into a positive impact company.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

Contact:

Tel: +33 (0)1 44 71 98 53

(C) 2021 Electronic News Publishing, source ENP Newswire